Ardelyx, Inc. (ARDX)
| Market Cap | 988.12M -21.1% |
| Revenue (ttm) | 450.89M +16.8% |
| Net Income | -55.70M |
| EPS | -0.23 |
| Shares Out | 247.03M |
| PE Ratio | n/a |
| Forward PE | 31.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,070,394 |
| Open | 4.050 |
| Previous Close | 4.870 |
| Day's Range | 3.900 - 4.270 |
| 52-Week Range | 3.900 - 8.400 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+257.5%) |
| Earnings Date | Aug 6, 2026 |
About ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an... [Read more]
Financial Performance
In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 257.50% from the latest price.
News
Ardelyx price target lowered to $15 from $19 at Raymond James
Raymond James lowered the firm’s price target on Ardelyx (ARDX) to $15 from $19 and keeps a Strong Buy rating on the shares. Ibsrela’s slower-than-expected trajectory suggests the thesis will…
Ardelyx price target lowered to $10 from $13 at TD Cowen
TD Cowen analyst Joseph Thome lowered the firm’s price target on Ardelyx (ARDX) to $10 from $13 and keeps a Buy rating on the shares. The firm updated its model…
Ardelyx price target lowered to $13 from $16 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Ardelyx (ARDX) to $13 from $16 and keeps a Buy rating on the shares.
Ardelyx reports Q2 EPS (7c), consensus (5c)
Reports Q2 revenue $118.13M, consensus $121.64M. “In the second quarter of 2026, we delivered combined revenue of $118 million, up 31% year over year, the largest quarterly revenue in our…
Ardelyx Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 31% year-over-year to $118 million, with IBSRELA and XPHOZAH both achieving record demand despite payer access hurdles. Full-year guidance for IBSRELA was lowered, but profitability is expected in 2027, and the company remains focused on pipeline expansion and disciplined capital allocation.
Ardelyx Earnings release: Q2 2026
Ardelyx released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ardelyx Quarterly report: Q2 2026
Ardelyx has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ardelyx Slides: Q2 2026
Ardelyx has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercializati...
Jefferies says Ardelyx CMS appeal loss ‘shouldn’t fundamentally change anything’
Jefferies notes that an appellate court this morning reaffirmed a district court’s decision and dismissed Ardelyx’s (ARDX) appeal on Xphozah getting included in the Medicare ESRD bundle and no longer…
Ardelyx assumed with a Buy at Ladenburg
Ladenburg assumed coverage of Ardelyx (ARDX) with a Buy rating and $16 price target The company’s focus is on growing demand for Ibsrela, maintaining sales momentum for Xphozah, expanding its…
Ardelyx Transcript: Jefferies Global Healthcare Conference 2026
Management outlined strong growth for IBSRELA and XPHOZAH, with 2026 revenue expected to exceed $500 million and ambitious long-term targets of $1 billion and $750 million, respectively. Strategic investments in sales, marketing, and R&D, along with new patent protection, support confidence in sustained growth and near-term profitability.
Ardelyx Proxy statement: Proxy filing
Ardelyx filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization...
Ardelyx Proxy statement: Proxy filing
Ardelyx filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines tha...
Ardelyx reports Q1 EPS (15c), consensus (14c)
Reports Q1 revenue $94.47M, consensus $92.61M. “In the first quarter of 2026, Ardelyx (ARDX) continued our strong commercial execution which coupled with our strengthening cash position allows us to c...
Ardelyx Earnings Call Transcript: Q1 2026
Q1 2026 saw 38% revenue growth, led by IBSRELA's 58% increase and XPHOZAH's 19% paid prescription growth. Guidance for 2026 and long-term targets were reiterated, with strong cash reserves and ongoing pipeline expansion supporting future growth.
Ardelyx Earnings release: Q1 2026
Ardelyx released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Ardelyx Quarterly report: Q1 2026
Ardelyx has published its Q1 2026 quarterly earnings report on April 30, 2026.
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million ...
Ardelyx Proxy statement: Proxy filing
Ardelyx filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select n...
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines t...
Jade Biosciences appoints Edward Conner as chief medical officer
Jade Biosciences (JBIO) announced the appointment of Edward Conner as chief medical officer, effective immediately. Conner joins Jade from Ardelyx (ARDX) where he served as CMO.